Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

Alkabbani W, Gamble JM

Drug Design, Development and Therapy 2021, 15:3057-3069

Published Date: 14 July 2021